K. Nahar
University of Sydney
14 Papers
17 Citations
K. Nahar is an academic researcher from University of Sydney. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 8 publications. Previous affiliations of K. Nahar include Royal North Shore Hospital.
Chat about Author
Papers
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
Grace H. Attrill,Carina N. Owen,Tasnia Ahmed,Ismael A. Vergara,Andrew J. Colebatch,Jordan Conway,K. Nahar,John F. Thompson,Ines Pires da Silva,G. Carlino,Alexander M. Menzies,Serigne Lo,Umaimainthan Palendira,Richard A. Scolyer,Georgina V. Long,James S. Wilmott +15 more
TL;DR: Adjuvant immunotherapy-treated patients with a high proportion of CD39+ Trms in their baseline melanoma resection have a significantly reduced risk of melanoma recurrence, and this population of T cells may not only represent a biomarker of RFS following anti-PD-1 therapy, but may also be an avenue for therapeutic manipulation and enhancing outcomes for Immunotherapy- treated patients with cancer.
Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma
Rajat Rai,Jennifer L. McQuade,Daniel Ying Wang,John J. Park,K. Nahar,J. A. Sosman,Kathryn E. Beckermann,Lauren E. Haydu,Serigne Lo,Samuel M. Rubinstein,Meredith Ann McKean,S. Matthew,Alexander Guminski,Matteo S. Carlino,Michael Davies,Douglas B. Johnson,Georgina V. Long,Alexander M. Menzies +17 more
15
Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis
K. Nahar,Felix Marsh-Wakefield,Robert V. Rawson,Tuba N. Gide,Angela Ferguson,R.O. Allen,Camelia Quek,Ines Pires da Silva,Stephen J. N. Tattersall,Christopher J. Kiely,Neomal S. Sandanayake,G. Carlino,Geoffrey W. McCaughan,James S. Wilmott,Richard A. Scolyer,Georgina V. Long,Alexander M. Menzies,Umaimainthan Palendira +17 more
TL;DR: Exaggerated innate and T cell responses to combination immunotherapy synergise to propel colitis in susceptible patients.
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series
Catriona Harvey,K. Nahar,Janet McKeown,Serigne N Lo,Sheima Farag,Nadia Yousaf,Kate Young,Liselotte Tas,Aafke Meerveld-Eggink,Christian Blank,Austin R. Thomas,Jennifer McQuade,Bastian Schilling,Douglas B. Johnson,Roberto Martín Huertas,A. Arance,Joanna Lee,Lisa Zimmer,G. V. Long,M. S. Carlino,Yinghong Wang,Alexander M. Menzies +21 more
TL;DR: CNIs appear most likely to result in toxicity resolution in the shortest time period, however, are associated with poorer oncological outcomes in contrast to vedolizumab.
5
Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy
K. Nahar,Robert V. Rawson,Neomal S. Sandanayake,S. Tattersal,Matteo S. Carlino,Umaimainthan Palendira,Richard A. Scolyer,Georgina V. Long,Alexander M. Menzies +8 more
TL;DR: Clically significant colitis due to immunotherapy varies in presentation, response to immunosuppression and endoscopic/histologic features, and IPI+PD1 colitis has an earlier onset, is more severe yet resistant to corticosteroids than PD1 induced colitis.
1